897666-34-1

Upstream product

• 371-41-5 4-Fluorophenol 
• 169457-73-2 tert-butyl 4-(2-bromoethyl)piperidine-1-carboxylate 
• 89151-44-0 4-(2-hydroxyethyl)piperidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 952055-51-5 2-{4-[2-(4-Fluoro-phenoxy)-ethyl]-piperidin-1-ylmethyl}-1-methyl-1H-benzoimidazole 
• 291289-20-8 4-(2-(4-fluorophenoxy)ethyl)piperidine 
• 141430-57-1 4-[2-(4-Fluoro-phenoxy)-ethyl]-piperidine Hydrochloride 

Relevant academic research and scientific papers

Synthesis of arrays using low molecular weight MPEG-assisted mitsunobu reaction

Triphenylphosphine tagged with a short poly(ethyleneglycol)-ω- monomethyl ether chain (light MPEG, 10-16 ethylenoxy units, MTPP-G2) and an MPEG-tagged version of diethyl azodicarboxylate (MDEAD) have been used to prepare a 20 member library of esters, ethers, and sulfonamides, with cLogP?s in the range of 1.4-5.7 on a 0.1 mmol scale. Removal of MPEG-tagged side products was achieved by MPEG-assisted solid-phase extraction (MSPE) on prepacked silica columns to give the products in good yield and high purity.

Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators

Compounds of Formula I: wherein A, B, D, L, R1, R2, R3, R4, m, and n are as defined for Formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.

Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators

The invention provides for a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein R1, R2, R3, A, B, D, m, n, x, and y are defined as described in the specification. The invention additionally provides a pharmaceutically composition comprising the compound of formula I, together with a method of using the same to treat or prevent neurological and psychiatric disorders. The compounds are useful in therapy related to the treatment or prevention of mGluR2 receptor-mediated disorders.

PYRAZOLONE COMPOUNDS AS METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS

Compounds of Formula (I), wherein R1, R2, R3, R4, R5, R6, X, and n are as defined for Formula (I) in the description, processes for the preparation of the compounds and new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and the use of the compounds in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction.